{"Clinical Trial ID": "NCT00278109", "Intervention": ["INTERVENTION 1:", "Experimental", "cyclophosphamide: chemotherapy", "Doxorubicin hydrochloride: chemotherapy", "- Adjuvant treatment: chemotherapy", "Radiotherapy: chemotherapy"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Histologically confirmed breast adenocarcinoma by routine hematoxyline and eosine (H&E) staining", "Primary tumour 4 cm and 0-3 axillary lymph nodes positive (pathological T1-2, N0-N1, pathological M0)", "Patients with positive lymph nodes only by cytokeratin staining (i.e., H&E negative) are eligible.", "No squamous breast carcinoma or squamous sarcoma", "Patients should have undergone segmental mastectomy (SM) with level I axillary dissection or sentinel lymph nodes biopsy in the last 14 weeks.", "The surgical margins at the time of SM must be negative (> 3 mm) for both invasive carcinomas and non-invasive ductal carcinomas", "No active local/regional disease", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "ECOG Performance Status 0-1", "Gender: female", "\u2022 Menopausal status not specified", "Not pregnant", "Negative pregnancy test", "Fertile patients should use effective non-hormonal contraception", "No other malignancy in the last 5 years, except skin cancer or in situ carcinoma of the treated basal cell or squamous cell", "No other serious or poorly controlled medical or psychiatric conditions that could be exacerbated by, or complicate compliance with study treatment", "THERAPE PRIOR CONCURENT:", "No previous radiation therapy in the breast", "No anterior trastuzumab (Herceptin \u00ae)", "No other concomitant chemotherapy", "No concomitant hormonal treatment except:", "Steroids administered for adrenal insufficiency", "- Hormones administered for non-disease-related conditions (e.g. insulin for diabetes, synthroid for hypothyroidism)", "Dexamethasone intermittently as antiemetic or premedication"], "Results": ["Performance measures:", "Number of participants with acute, late skin and subcutaneous toxicity", "Number of participants with Grade 4 toxicity according to the following criteria:", "Acute toxicity of the skin: 0=No modification, 1= follicular erythema, weak or dull/epilation/dry/desquamation/degenerate swelling, 2= Moderate erytemic desquamation/edema, 3= Confluent wet dequamation other than skin folds, prickly oedema, 4= Ulceration, hemorrhage, necrosis, Late skin toxicity: 0= None, 1= Mild atrophy, pigmentation change, hair loss, 2= Atrophy of the skin, moderate telangectasis, total hair loss, 3= Marked atrophy, crude telangectasis, 4= Ulceration; Subcutaneous toxicity of subcutaneous tissue: 0= None, 1= Mild induration (fibrosis) and loss of subcutaneous fat, 2= Moderate but asymptomatic fibrosis; slight linear reduction of field, <10%, 3= Loss of subcutaneous tissue; decrease in field >10%; linear reduction; 4=", "Time limit: up to 5 years", "Results 1:", "Title of the arm/group: Experimental", "Description of the arm/group: cyclophosphamide: chemotherapy", "Doxorubicin hydrochloride: chemotherapy", "- Adjuvant treatment: chemotherapy", "Radiotherapy: chemotherapy", "Total number of participants analysed: 25", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/25 (4.0 per cent)", "Neutropenia *1/25 (4.0%)"]}